Extended Data Fig. 8: δ1 and reservoir levels pre-intervention.

a. Comparison of \({\delta }_{1}\) between groups. Controls (n = 12), RhmAb + AZD5582 (n = 9), and RhmAb + AZD5582 + N-803 (n = 9). Statistical significance was determined with a two-sided Mann-Whitney U test. Horizontal lines represent the median. NS = non-significant. b. Correlation between \({\delta }_{1}\) and levels of CD4 + T cell-associated SIV-DNA in all RMs at weeks 81–87 before treatment with RhmAbs, AZD5582, or N-803 in lymph nodes (LN), peripheral blood (PB), bone marrow (BM), and gastrointestinal (GI) tract. c. Correlation between δ1 and the fold change in SIV-DNA in LN CD4+ T cells for each group that received RhmAbs. Nonparametric two-sided Spearman correlation with 95% confidence interval was used for statistical analysis in (B) and (C).